Chimeric Therapeutics Limited Overview
Get informed when a big investor buys or sells
+ Follow329.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Chimeric Therapeutics Limited (CHMMF) currently reports a ROE of 329.59%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Chimeric Therapeutics Limited's ROE history and peer comparisons.
Chimeric Therapeutics Limited's ROE of 329.59% is higher than the Healthcare sector average of -100.59%. That is roughly 427.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Chimeric Therapeutics Limited's current 329.59% should be judged against Healthcare norms (sector average: -100.59%) and against CHMMF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 329.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Chimeric Therapeutics Limited, and consider following CHMMF for alerts when major investors trade the stock.
Chimeric Therapeutics Limited is classified in the Healthcare sector. On ROE, it currently shows 329.59% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CHMMF with unrelated industries.
